Drug class
Benzodiazepine anxiolytic; positive allosteric modulator of GABAA receptors
Mechanism of action
Prazepam is metabolised to active benzodiazepine metabolites, including nordazepam, which positively modulate GABAA receptor activity at the benzodiazepine binding site and enhance GABA-mediated neuronal inhibition.
General use cases
- Short-term treatment of anxiety disorders in countries where prazepam remains authorised; long-term use is limited by tolerance, dependence, sedation and withdrawal risk
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
